Download PDF
Semin Neurol 2003; 23(1): 083-088
DOI: 10.1055/s-2003-40755
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

The Edrophonium Test

Robert M. Pascuzzi
  • Professor and Associate Chair, Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana
Further Information

Publication History

Publication Date:
21 July 2003 (online)

    Permissions and Reprints

ABSTRACT

Cholinesterase inhibitors (CEIs) have been known to improve strength in patients with myasthenia gravis (MG) since the 1930s, and have been used as a diagnostic test since the early 1950s. The following review summarizes the history of edrophonium usage in myasthenia gravis, reviews the literature with regard to the method of performing the edrophonium test, and discusses the available information regarding sensitivity and specificity of the test with respect to diagnosis of MG.

KEYWORDS

Edrophonium test - Tensilon test - myasthenia gravis - diagnostic testing - cholinesterase inhibitors

REFERENCES

  • 1 Jolly F. Uber myasthenia gravis pseudoparalytica.  Berl Klin Wochenschr . 1895;  32 1-7
    PubMedGoogle Scholar
  • 2 Murri A. Sur un cas de maladie d'Erb.  Arch Ital Biol . 1896;  25 64-92
    PubMedGoogle Scholar
  • 3 Remen L. Zur pathogenese und therapie der myasthenia gravis pseudoparalytica.  Dtsch Nervenklinik . 1932;  128 66-78
    PubMedGoogle Scholar
  • 4 Walker M B. Treatment of myasthenia gravis with physostigmine.  Lancet . 1934;  1 1200-1201
    PubMedGoogle Scholar
  • 5 Keynes G. The history of myasthenia gravis. The Grey Turner Memorial Lecture, University of Durham, 1961: 313-326
    Google Scholar
  • 6 Walker M B. Case showing the effect of prostigmin on myasthenia gravis.  Proc R Soc Med . 1935;  28 759-761
    PubMedGoogle Scholar
  • 7 Pritchard E AB. The use of prostigmin in the treatment of myasthenia gravis.  Lancet . 1935;  4 32-34
    PubMedGoogle Scholar
  • 8 Macfarlane D W, Pelikan E W, Unna K R. Evaluation of curarizing drugs in man.  J Pharmacol Exp Ther . 1950;  100 382-392
    PubMedGoogle Scholar
  • 9 Westerberg M R, Magee K R, Shideman F. Effect of 3-hydroxy phenyldimethylethylammonium chloride (Tensilon) in myasthenia gravis.  Univ Michigan Med Bulletin . 1951;  17 311-316
    PubMedGoogle Scholar
  • 10 Westerberg M R, Magee K R, Shideman F E. Effect of Tensilon in myasthenia gravis.  Neurology . 1953;  3 302-305
    PubMedGoogle Scholar
  • 11 Osserman K E, Kaplan L I. Rapid diagnostic test for myasthenia gravis.  JAMA . 1952;  150 265-268
    CrossrefPubMedGoogle Scholar
  • 12 Osserman K E, Kaplan L I. Studies in myasthenia gravis.  Arch Neurol Psych . 1953;  70 385-392
    PubMedGoogle Scholar
  • 13 Osserman K E, Kaplan L I, Besson G. Studies in myasthenia gravis: edrophonium chloride (Tensilon) test as a new approach to management.  J Mt Sinai Hosp . 1953;  20 165-172
    PubMedGoogle Scholar
  • 14 Osserman K E, Genkins G. Critical reappraisal of the use of edrophonium (Tensilon) chloride tests in myasthenia gravis and significance of clinical classification.  Ann N Y Acad Sci . 1966;  135 312-334
    PubMedGoogle Scholar
  • 15 Tether J E. Mestinon in myasthenia gravis: preliminary report.  Dis Nerv Syst . 1954;  15 227-231
    PubMedGoogle Scholar
  • 16 Westerberg M R, Magee K R. Mestinon in the treatment of myasthenia gravis.  Neurology . 1954;  4 762-772
    PubMedGoogle Scholar
  • 17 Schwab R S, Timberlake W H. Pyridostigmine (Mestinon) in the treatment of myasthenia gravis.  N Engl J Med . 1954;  251 271-272
    PubMedGoogle Scholar
  • 18 Osserman K E, Teng P, Kaplan L I. Studies in myasthenia gravis: preliminary report on therapy with mestinon bromide.  JAMA . 1954;  155 961-965
    PubMedGoogle Scholar
  • 19 Seybold M E. The office Tensilon test for ocular myasthenia gravis.  Arch Neurol . 1986;  43 842-843
    CrossrefPubMedGoogle Scholar
  • 20 Daroff R B. The office tensilon test for ocular myasthenia gravis.  Arch Neurol . 1986;  33 843-844
    PubMedGoogle Scholar
  • 21 Barton J S, Fouladvan D. Ocular aspects of myasthenia gravis.  Sem Neurol . 2000;  20 7-20
    PubMedGoogle Scholar
  • 22 Miller N, Morris J, Maquire M. Combined use of neostigmine and ocular motility measurements in the diagnosis of myasthenia gravis.  Arch Ophthalmol . 1982;  100 761-763
    PubMedGoogle Scholar
  • 23 Spector R H, Daroff R B. Edrophonium infrared optokinetic nystagmography in the diagnosis of myasthenia gravis.  N Y Acad Sci . 1976;  274 642-651
    PubMedGoogle Scholar
  • 24 Nicholson G A, McLeod J G, Griffiths L R. Comparison of diagnostic tests in myasthenia gravis.  Clin Exp Neurol . 1983;  19 45-49
    PubMedGoogle Scholar
  • 25 Kelly Jr J J, Daube J R, Lennon V A, Howard Jr M F, Younge B R. The laboratory diagnosis of mild myasthenia gravis.  Ann Neurol . 1982;  12 238-242
    CrossrefPubMedGoogle Scholar
  • 26 Beekman R, Kuks J BM, Oosterhuis H G H J. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients.  J Neurol . 1997;  244 112-118
    PubMedGoogle Scholar
  • 27 Padua L, Stalberg E, LoMonaco M, Evoli A, Batocchi A, Tonali P. SFEMG in ocular myasthenia gravis diagnosis.  Clin Neurophysiol . 2000;  111 1203-1207
    CrossrefPubMedGoogle Scholar
  • 28 Evoli A, Tonali P, Bartoccioni E, Lo Monaco M. Ocular myasthenia: diagnostic and therapeutic problems.  Acta Neurol Scand . 1988;  77 31-35
    CrossrefPubMedGoogle Scholar
  • 29 Phillips II H L, Melnick P A. Diagnosis of myasthenia gravis in the 1990s.  Semin Neurol . 1990;  10 62-69
    PubMedGoogle Scholar
  • 30 Oh S J, Cho H K. Edrophonium responsiveness not necessarily diagnostic of myasthenia gravis.  Muscle Nerve . 1990;  13 187-191
    PubMedGoogle Scholar
  • 31 Edell T A, Sullivan Jr P C, Osborn K M, Gambin J P, Brenman R D. Wound botulism associated with a positive tensilon test.  West J Med . 1983;  139 218-219
    PubMedGoogle Scholar
  • 32 Maselli R, Jacobsen J H, Spire J P. Edrophonium: an aid in the diagnosis of acute organophosphate poisoning.  Ann Neurol . 1986;  19 508-510
    CrossrefPubMedGoogle Scholar
  • 33 Moorthy G, Behrens M M, Drachman D B. et al . Ocular pseudomyasthenia or ocular myasthenia plus a warning to clinicians.  Neurology . 1989;  39 1150-1154
    CrossrefPubMedGoogle Scholar
  • 34 Mulder D W, Lambert E H, Eaton L M. Myasthenic syndrome in patients with ALS.  Neurology . 1959;  9 627-631
    PubMedGoogle Scholar
  • 35 Dirr L Y, Donofrio P D, Patton J F, Troost B T. A false-positive edrophonium test in a patient with a brainstem glioma.  Neurology . 1989;  39 865-867
    CrossrefPubMedGoogle Scholar
  • 36 Mindel J S, Charney J Z. Bilateral intracavernous carotid aneurysms presenting as pseudoocular myasthenia gravis.  Trans Am Ophthalmol Soc . 1989;  87 445-457
    PubMedGoogle Scholar
  • 37 Diamond S, Schear H E, Leeds M F. Pseudointernuclear oculomotor ophthalmoplegia secondary to Guillain-Barré polyneuritis simulating myasthenia gravis in an air transport pilot.  Aviat Space Environ Med . 1975;  46 204-207
    PubMedGoogle Scholar
  • 38 Khan G A, Bank N. Interpretation of positive edrophonium (Tensilon) test in patients with end-stage renal disease.  Ren Fail . 1995;  17 65-71
    PubMedGoogle Scholar
  • 39 Ing E B, Ing S Y, Ing T, Ramocki J A. The complication rate of edrophonium testing for suspected myasthenia gravis.  Can J Ophthalmol . 2000;  35 141-145
    PubMedGoogle Scholar
  • 40 Nucci P, Brancato R. Oculogyric crisis after the Tensilon test.  Graefes Arch Clin Exp Ophthalmol . 1990;  228 384-385
    PubMedGoogle Scholar
  • 41 Hodes R. Electromyographic study of defects of neuromuscular transmission in human poliomyelitis.  Arch Neurol Psych . 1948;  60 457-473
    PubMedGoogle Scholar
  • 42 Ragge N K, Hoyt W F. Midbrain myasthenia: fatigable ptosis, lid twitch sign, and opthalmoparesis from a dorsal midbrain glioma.  Neurology . 1992;  42 917-919
    PubMedGoogle Scholar
  • 43 Straube A, Witt T. Oculobulbar myasthenic symptoms as the sole sign of a tumor involving or compressing the brain stem.  J Neurol . 1990;  237 369-371
    PubMedGoogle Scholar
      >